NADPH tetrasodium salt

SKU: orb1300081

Description

This reduced, tetrasodium salt form of NADPH serves as a critical electron donor in biosynthetic and detoxification pathways. It is widely used in vitro to study cellular redox balance and enzymology, and has been identified as a key endogenous inhibitor of ferroptosis in related research models.

Research Area

Cell Biology, Metabolism Research

Images & Validation

−

Key Properties

−

CAS Number	2646-71-1
MW	833.35
Purity	99.99% (May vary between batches)
Formula	C₂₁H₂₆N₇Na₄O₁₇P₃
SMILES	[Na+].[Na+].[Na+].[Na+].NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OC[C@H]2O[C@H]([C@H](OP([O-])([O-])=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O
Target	Endogenous Metabolite,Ferroptosis
Solubility	H2O:35 mg/mL (42 mM);DMSO:1.25 mg/mL (1.5 mM)

Bioactivity

−

In Vivo

METHODS: To examine the effects on Kainic acid (KA)-induced excitotoxicity and its mechanism, NADPH tetrasodium salt (1-2 mg/kg in saline) was administered intravenously to KA-induced rats once a day for seven days. RESULTS: NADPH reduced KA-induced increase in striatal lesion size, improved KA-induced dyskinesia, and reversed KA-induced glial cell activation. METHODS: NADPH tetrasodium salt (2.5 mg/kg) was intravenously injected into ICR mice to determine whether exogenous NADPH could enter the brain tissues and neurons of mice. RESULTS: Injection of NADPH significantly increased the levels of NADPH in the blood and brain tissue of mice.The half-life of NADPH in the blood of mice is about 6 h and in the brain tissue is 7 h.

In Vitro

METHODS: Neurons were pretreated with NADPH tetrasodium salt (2.5-10 μM) for 1-8 h, then treated with Kainic acid (KA, 100 μM) for 8 h. Cell viability was measured by CCK-8 assay. RESULTS: KA treatment significantly reduced the cell viability of primary cortical neurons in a time-dependent and dose-dependent manner, and NADPH pretreatment significantly promoted neuronal survival, which was more effective at 10 μM for 4 or 8 h. The RESULTS showed that Kainic acid (KA, 100 μM) treatment significantly reduced the cell viability of primary cortical neurons. METHODS: Neurons were pretreated with NADPH tetrasodium salt (10 μM) for 4 h, and then treated with Kainic acid (KA, 100 μM) for 8 h. The expression levels of target proteins were detected by Western Blot. RESULTS: The expression of TIGAR was decreased after KA treatment, and it was significantly reversed by NADPH.

Storage & Handling

−

Storage	-20°C
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

proteins, lipid, inhibit, pathways, metabolic, nucleotides, NADPH tetrasodium, NADPH tetrasodium salt, NADPH, EndogenousMetabolite, Endogenous Metabolite, fatty, Ferroptosis, Inhibitor, acids, biosynthetic, cofactor

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

52945042 ↗

Key Properties

−

No computed properties available.

Protocol Information

Find More Protocols

Purity:	>98% (HPLC)
CAS Number:	2646-71-1
MW:	833.35
Formula:	C₂₁H₂₆N₇Na₄O₁₇P₃

NADPH tetrasodium salt

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products